CG Oncology (NASDAQ:CGON) Given “Buy” Rating at HC Wainwright

CG Oncology (NASDAQ:CGON)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They currently have a $75.00 target price on the stock. HC Wainwright’s price objective suggests a potential upside of 162.88% from the stock’s current price.

Other analysts have also issued research reports about the stock. Morgan Stanley reiterated an “overweight” rating and issued a $55.00 target price on shares of CG Oncology in a research report on Friday, March 7th. TD Cowen began coverage on CG Oncology in a report on Tuesday, January 7th. They issued a “buy” rating on the stock. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $66.00 price objective on shares of CG Oncology in a research note on Friday, December 6th. Nine analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $63.88.

CG Oncology Price Performance

CG Oncology stock opened at $28.53 on Tuesday. The company’s fifty day moving average price is $28.08 and its 200 day moving average price is $32.09. CG Oncology has a 1 year low of $23.91 and a 1 year high of $46.99.

Insider Transactions at CG Oncology

In related news, Director Leonard E. Post sold 1,000 shares of CG Oncology stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $29.66, for a total transaction of $29,660.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Institutional Trading of CG Oncology

Hedge funds and other institutional investors have recently modified their holdings of the stock. GF Fund Management CO. LTD. purchased a new stake in shares of CG Oncology in the fourth quarter valued at about $41,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in CG Oncology in the 4th quarter valued at about $68,000. KLP Kapitalforvaltning AS acquired a new position in CG Oncology in the 4th quarter valued at about $100,000. Federated Hermes Inc. purchased a new stake in shares of CG Oncology in the 4th quarter valued at approximately $172,000. Finally, Meeder Asset Management Inc. acquired a new stake in shares of CG Oncology during the 4th quarter worth approximately $189,000. 26.56% of the stock is owned by institutional investors and hedge funds.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.